| Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance RJ Verheijden, MJM van Eijs, AM May, F van Wijk, KPM Suijkerbuijk NPJ precision oncology 7 (1), 41, 2023 | 51 | 2023 |
| Clinical and translational attributes of immune-related adverse events KPM Suijkerbuijk, MJM van Eijs, F van Wijk, AMM Eggermont Nature Cancer 5 (4), 557-571, 2024 | 30 | 2024 |
| Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma RJ Verheijden, FH Burgers, JC Janssen, AE Putker, SPGR Veenstra, ... European Journal of Cancer 207, 114172, 2024 | 15 | 2024 |
| Toxicity-specific peripheral blood T and B cell dynamics in anti-PD-1 and combined immune checkpoint inhibition MJM van Eijs, RJ Verheijden, SA van der Wees, S Nierkens, ... Cancer Immunology, Immunotherapy 72 (12), 4049-4064, 2023 | 15 | 2023 |
| Innovative perspective: gadolinium-free magnetic resonance imaging in long-term follow-up after kidney transplantation MJM Van Eijs, AD Van Zuilen, A De Boer, M Froeling, TQ Nguyen, ... Frontiers in Physiology 8, 296, 2017 | 12 | 2017 |
| Hematologic malignancies following immune checkpoint inhibition for solid tumors MJM van Eijs, LE van der Wagen, R Mous, RJ Leguit, L van de Corput, ... Cancer Immunology, Immunotherapy 72 (1), 249-255, 2023 | 7 | 2023 |
| Physical activity and checkpoint inhibition: association with toxicity and survival RJ Verheijden, A Cabané Ballester, KC Smit, MJM van Eijs, CP Bruijnen, ... JNCI: Journal of the National Cancer Institute 116 (4), 573-579, 2024 | 6 | 2024 |
| Checkpoint inhibition: protecting against or predisposing for second primary tumors? KPM Suijkerbuijk, AM May, MJM van Eijs Annals of Oncology 32 (7), 935, 2021 | 5 | 2021 |
| Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies OJ Van Not, AJM van den Eertwegh, JB Haanen, RS van Rijn, MJB Aarts, ... European Journal of Cancer 186, 27-37, 2023 | 3 | 2023 |
| Highly multiplexed spatial analysis identifies tissue-resident memory T cells as drivers of ulcerative and immune checkpoint inhibitor colitis MJM van Eijs, JJM Ter Linde, MJD Baars, M Amini, MM Laclé, EC Brand, ... Iscience 26 (10), 2023 | 2 | 2023 |
| Platelet RNA splicing profiles can distinguish IgM MGUS patients from healthy individuals MJM Van Eijs, NC Notermans, T Würdinger, MC Minnema Blood 134, 3771, 2019 | 1 | 2019 |
| Gut microbiome and immune checkpoint inhibitor toxicity RJ Verheijden, MJM van Eijs, FL Paganelli, MC Viveen, MRC Rogers, ... European Journal of Cancer 216, 115221, 2025 | | 2025 |
| Tumor-infiltrating lymphocytes and immune-related adverse events in advanced melanoma IAJ van Duin, M Schuiveling, LS Ter Maat, M Veta, MJM van Eijs, ... Immuno-Oncology and Technology 24, 100714, 2024 | | 2024 |
| In vitro T cell responses to PD-1 blockade are reduced by IFN-α but do not predict therapy response in melanoma patients LM Timmerman, LCM Hensen, MJM van Eijs, RJ Verheijden, ... Cancer Immunology, Immunotherapy 73 (9), 181, 2024 | | 2024 |
| Blood and tissue correlates of steroid non-response in checkpoint inhibition-induced immune-related adverse events MJM van Eijs, MM van der Wal, HB Klotškova, NMM Dautzenberg, ... medRxiv, 2024.12. 04.24318205, 2024 | | 2024 |
| Association between physical activity, immune-related adverse events, and mortality in patients undergoing immune checkpoint inhibition. RJ Verheijden, A Cabane Ballester, MJM van Eijs, ASR van Lindert, ... Journal of Clinical Oncology 41 (16_suppl), 2643-2643, 2023 | | 2023 |
| 1667P Multiplexed spatial analysis by imaging mass cytometry to immunologically characterize checkpoint inhibitor colitis M Van Eijs, JJM ter Linde, MJD Baars, MM Amini, MM Laclé, EC Brand, ... Annals of Oncology 33, S1305-S1306, 2022 | | 2022 |
| Student-driven education; catalyst of change in medical curriculum MJM van Eijs, RN Casteleijn, ML de Weerd, SJJ Bos Nederlands Tijdschrift Voor Geneeskunde 162, D2998-D2998, 2018 | | 2018 |
| Student-gedreven onderwijs katalysator van veranderingen in het medisch curriculum M van Eijs, R Casteleijn, M de Weerd, S Bos Nederlands Tijdschrift voor Geneeskunde 162 (39), 2018 | | 2018 |
Karijn SuijkerbuijkHoogleraar immuuntherapie, UMC Utrechtبريد إلكتروني تم التحقق منه على umcutrecht.nl